Insulin glargine: the first clinically useful extended-acting insulin in half a century?

Bibliography

• HOME PD: Insulin therapy. In: The International Text-book of Diabetes (second edition). Alberti KGMM, Zimmet P, Defronzo RA (Eds.), Wiley, Chichester, UK (1996) :899–928.
   Google Scholar
• SCOTT DA, FISHER AM: Studies on insulin with prota-mine. J. Pharmacol. Exp. Ther. (1936) 58:78–92.
   Google Scholar
• KRAYENBOHL C, ROSENBERG T: Crystalline protamine insulin. Rep. Steno. Hosp. (1946) 1:60–73.
   Google Scholar
• HALLAS-MOLLER K, PETERSEN K, SCHLICHTKRULL J: Crystalline and amorphous insulin-zinc compounds with prolonged action. Science (1952) 116:394–399.
   PubMed Web of Science ®Google Scholar
• HEINE R, BILO HGJ, SIKKENCK AC: Mixing short and in-termediate acting insulins in the syringe: effect on postprandial blood glucose concentrations in Type 1 diabetics. Br. Med. J. (1985) 290:204–205.
   PubMed Web of Science ®Google Scholar
• ALBERTI KGMM: Insulin treatment and diabetes: half acentury of therapeutic misadventure? In: Advanced medicine. Tunbridge WMG (Ed.), Pitman, Bath, UK (1981):1–13.
   Google Scholar
• THOW JC, JOHNSTON AB, ANTISEROV M, HOME PD: Ef-fect of raising injection site temperature on isophane insulin crystal dissociation. Diabetes Care (1989) 12:432–434.
   PubMed Web of Science ®Google Scholar
• LAURITZEN T, PRAMMING S, GALE E, DECKERT T,BINDER C: Absorption of isophane (NPH) insulin and its clinical implications. Br. Med. J. (1982) 285:159–162.
   PubMed Web of Science ®Google Scholar
• TCHOBROUTSKY G: Relation of diabetic control to de-velopment of microvascular complications. Diabetolo-gia (1978) 15:143–152.
   PubMed Web of Science ®Google Scholar
• BRANGE J, RIBEL U, HANSEN JF eta].: Monomeric insulinobtained by protein engineering and their medical im-plications. Nature (1988) 333:679–682.
   Google Scholar
• MARKUSSEN J, HOUGAARD P, RIBEL U, SORENSEN AR,SORENSEN E: Soluble prolonged-acting insulin deriva-tives. I. Degree of protraction and crystallizability of insulin substituted in the termini of the B-chain. Pro-tein Eng. (1987) 1:205–213.
   Google Scholar
• DEHAEN C, LITTLE SA, MAY JM, WILLIAMS RH: Charac-terization of proinsulin-insulin intermediates in hu-man plasma. J. Clin. Invest. (1978) 62:727–737.
   PubMed Web of Science ®Google Scholar
• JORGENSEN S, VAAG A, LANGKJAER L, HOUGAARD P,MARKUSSEN J: NovoSol Basal: pharmacokinetics of a novel soluble long acting insulin analog. Br. Med. J. (1989) 299:415–419.
   PubMed Web of Science ®Google Scholar
• HOLMAN RR, STEEMSON J: OPID 174: a novel long-acting insulin preparation. Diabetic Med. (1989) 6(1):A41.
   Google Scholar
• ZEUZEM S, STAHL E, JUNGMANN E, ZOLTOBROCKI M,SCHOFFLING K, CASPARY WF: In vitro activity of bio-synthetic human diarginylinsulin. Diabetologia (1990) 33:65–71.
   PubMed Web of Science ®Google Scholar
• JORGENSEN LN, DIDERIKSEN LH, DREJER K: Carcino-genic effect of human insulin analogue BlOAsp in fe-male rats. Diabetologia (1992) 35(1):A3.
   Google Scholar
• BAHR M, KOLTER T, SEIPKE G, ECKEL J: Growth promot-ing and metabolic activity of the human insulin ana-logue (G1yA21, ArgB31, ArgB32)insulin (HOE 901) in muscle cells. Eur. j Pharmacol. (1997) 320:259–265.
   PubMed Web of Science ®Google Scholar
• BERTI L, KELLERER M, BOSSENMAIER B, SEFFER E, SEIPKEE, HARING H U: The long acting human insulin analog HOE 901: Characteristics of insulin signalling in com-parison to Asp(B10) and regular insulin. Horm. Metab. Res. (1998) 30:123–129.
   PubMed Web of Science ®Google Scholar
• SEIPKE G, GEISEN K, NEUBAUER H P, PITTIUS C,ROBKAMP R, SCHWABE D: New insulin preparations with prolonged action profiles: A21-modified arginine insulins. Diabetologia (1992) 35 (1) :A4.
   Google Scholar
• DREYER M, PEIN M, SCHMIDT C, HEIDTMANN B, SCHLONZEN M, ROBKAMP D: Comparison of the phar-macokinetics/dynamics of GLY(A21) ARG(B31,B32) human insulin (HOE71GT) with NPH insulin following subcutaneous injection by using euglycaemic clamp technique. Diabetologia (1994) 37(1) :A78.
   Google Scholar
• SOON PC, MATTHEWS DR, ROSSKAMP R, HERZ M, KURZ-HALS R: 24h profile of action of biosynthetic long act-ing insulin (HOE 901) tested in normal volunteers by glucose clamp methodology. Diabetes (1997) 46(1):161A.
   PubMedGoogle Scholar
• OWENS D, LUZIO S, TINBERGEN J, KURZHALS R: The ab-sorption of HOE 901 in healthy subjects. Diabetologia (1998;) 41(1):A245.
   PubMedGoogle Scholar
• OWENS D, LUZIO S, BECK P, COATES P, TINBERGEN J,KURZHALS R: The absorption of the insulin analogue HOE 901 from different sites in healthy subjects. Diabe-tes (1997) 46(1):329A.
   Google Scholar
• GARG S, GERARD L, PENNINGTON M, MECCA T, TAYLOR L, CHASE P, JENNINGS K: Efficacy of the new long acting insulin analog (HOE 901) on fasting glucose values in IDDM. Diabetes (1998) 47(1) :A359.
   Google Scholar
• TALAULICAR M, WILLMS B, ROSSKAMP R: Efficacy of HOE 901 following subcutaneous injection for four days in Type I diabetic subjects. Diabetologia (1994) 37(1) :A169.
   Google Scholar
• PIEBER T, EUGENE-JOLCHINE I, DEROBERT E: Efficacy and safety of HOE 901 in patients with Type 1 diabetes: a four week randomised, NPH insulin controlled trial. Diabetes (1998) 47(1):A62.
   Google Scholar
• ROSENSTOCK J, PARK G, ZIMMERMAN J: Efficacy and safety of HOE 901 in patients with Type 1 DM: a four week randomized, NPH insulin controlled trial. Diabe-tes (1998) 47(1):A92.
   Google Scholar
• RASKIN P, PARK G, ZIMMERMAN J: The effect of HOE 901 on glycemic control in Type 2 diabetes. Diabetes (1998) 47(1):A103.
   Google Scholar
• MATTHEWS DR, PFEIFFER C: A new long acting insulin (HOE 901) demonstrates less nocturnal hypoglycae-mia when compared with protamine insulin in a clini-cal trial. Diabetologia (1998) 41 (1):A245.
   PubMedGoogle Scholar
• PIEBER TR, EUGENE-JOLCHINE I, DEROBERT E: Efficacy and safety of HOE 901 in patients with Type 1 diabetes: a four week randomised, NPH insulin controlled trial. Diabetologia (1998) 41(1):A49.
   PubMedGoogle Scholar